We recently published 10 Most Undervalued Pharma Stocks To Buy Now. Novartis AG stands third among the most undervalued stocks. Novartis AG (NYSE:NVS) is a Swiss pharmaceutical leader focused on ...

Novartis has claimed accelerated approval from the FDA for Vanrafia, one of a trio of therapies it hopes will revolutionise the treatment of rare kidney disease IgA nephropathy (IgAN). Vanrafia ...

Swiss pharma giant Novartis AGNVS reported better-than-expected results for the second quarter of 2025 and upped annual guidance for core operating income. Core earnings (excluding one-time charges) ...

Vanrafia (atrasentan) recently received FDA accelerated approval for reducing proteinuria in IgA nephropathy, marking a key advancement. Fabhalta (iptacopan), an oral treatment for C3 glomerulopathy, ...

From a competitive standpoint, the market is becoming increasingly dynamic. New entrants like Novartis' VANRAFIA and Travere Therapeutics' FILSPARI are giving tough competition to TARPEYO/KINPEYGO.

Q2 2025 Earnings Call Transcript July 21, 2025 Operator: Good morning and good afternoon, and welcome to the Novartis Q2 2025 ...

Vanrafia (atrasentan) FDA accelerated approval for IgAN OAV101 IT US and EU submissions for SMA Votoplam Phase II PIVOT-HD study positive readout in Huntington's disease ...

Read also: Novartis receives USFDA accelerated approval for Vanrafia for proteinuria reduction in primary IgA nephropathy Novartis stock was down more than 2% on Friday morning. The company said in a ...

Vera Therapeutics' Phase 3 data on atacicept sparks optimism for IgAN treatment, but competition and market challenges may ...